Project overview Joint Funding

Afatinib (Afatinib in NRG1-rearranged KRAS wild-type malignancies)

Program: MTT Funding Line: INNOVATION Project type: IIT/clinical study Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: pancreatic cancer Status: completed

AMI2GO (Amplify Immunological Insights by Glioma Organoids)

Program: CI Funding Line: UPGRADE Project type: study-related research project Partner site: Berlin, Frankfurt/Mainz, Heidelberg Entity: brain tumor Status: current

AMPLIFY-NEOVAC (Amplifying Neoepitope-specific Vaccine Responses in progressive diffuse gliomas)

Program: CI Funding Line: INNOVATION Project type: IIT/clinical study Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Heidelberg, Munich, Tubingen Entity: brain tumor Status: current

ARMANI (Resection of liver mets in patients with RAS-mutated CoCa)

Program: MDEB Funding Line: INNOVATION Project type: IIT/clinical study Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: colon cancer Status: current

CAR2BRAIN (Immune response CAR-NK immunotherapy in glioblastoma)

Program: CI Funding Line: UPGRADE Project type: study-related research project Partner site: Dresden, Frankfurt/Mainz, Heidelberg Entity: brain tumor Status: completed

CD276xCD3 (FIH study evaluating CR276xCD3 bsAb CC-3 in CRC)

Program: CI Funding Line: INNOVATION Project type: IIT/clinical study Partner site: Berlin, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: colon cancer Status: current

CHOICE (Osteo-hematopoietic niche & malignant evolution)

Program: EOM Funding Line: INNOVATION Project type: research project Partner site: Dresden, Frankfurt/Mainz, Munich Entity: blood cancer Status: completed

Decode-UM (Decoding the cellular ecosystem of uveal melanoma for monitoring and therapeutic targeting)

Program: CI Funding Line: INNOVATION Project type: research project Partner site: Berlin, Essen/Dusseldorf, Heidelberg, Tubingen Entity: skin cancer Status: current

DKTK Surgery (Individualized surgical oncology of gastrointestinal tumors)

Programs: Overarching Funding Line: strategic initiative Project type: research project Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: colon cancer, pancreatic cancer Status: completed

EPIC-G8 (GeparOcto-methylation profiling)

Program: MDEB Funding Line: UPGRADE Project type: study-related research project Partner site: Berlin, Heidelberg, Munich Entity: breast cancer Status: completed

Evaluation of New Therapeutic Concepts in Relapsed AML

Program: MTT Funding Line: INNOVATION Project type: research project Partner site: Berlin, Dresden, Frankfurt/Mainz, Freiburg, Munich Entity: blood cancer Status: completed

EXLIQUID (ExploitLiquid)

Program: MDEB Funding Line: INNOVATION Project type: research project Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: multiple entities Status: current

Ga-PSMA-11 in high-risk prostate cancer

Program: ROI Funding Line: INNOVATION Project type: IIT/clinical study Partner site: Berlin, Dresden, Essen/Dusseldorf, Freiburg, Heidelberg, Munich, Tubingen Entity: prostate cancer Status: completed

HematoTrac (Hematopoietic trajectories in cancer)

Program: EOM Funding Line: INNOVATION Project type: research project Partner site: Essen/Dusseldorf, Frankfurt/Mainz, Freiburg Entity: brain tumor Status: current

HYPERBOLIC (Hyperpolarized MRI of Cancer Metabolism & Markers)

Program: ROI Funding Line: INNOVATION Project type: research project Partner site: Freiburg, Heidelberg, Munich, Tubingen Entity: brain tumor, breast cancer Status: current

IDENTI-T (Precision monitoring and targeting of T-ALL)

Program: MDEB Funding Line: UPGRADE Project type: study-related research project Partner site: Berlin, Frankfurt/Mainz, Heidelberg Entity: blood cancer Status: current

IMMUNED (Predictive Biomarker for Adjuvant Immunotherapy)

Program: CI Funding Line: UPGRADE Project type: study-related research project Partner site: Essen/Dusseldorf, Heidelberg, Tubingen Entity: skin cancer Status: current

ImmuNeoMASTER (Impact of mutational pathways on immune environment, neoantigens and tumor rejection for the development of comprehensive biomarker panels and combinatorial approaches in cancer immunotherapy)

Program: CI Funding Line: INNOVATION Project type: research project Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: multiple entities Status: completed

INFORM (Individualized Therapy for Relapsed Malignancies in Childhood)

Program: MDEB Funding Line: INNOVATION Project type: research project Partner site: Berlin, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: cancer in childhood and adolescence, multiple entities Status: completed

INFORM/MASTER PRO

Program: MTT Funding Line: UPGRADE Project type: study-related research project Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: multiple entities Status: completed

INVENT4GB (Intraventricular TCR therapy for glioblastoma)

Program: CI Funding Line: INNOVATION Project type: IIT/clinical study Partner site: Berlin, Frankfurt/Mainz, Heidelberg, Tubingen Entity: brain tumor Status: current

IVAC-AN (Neoantigen Recognition by Vaccine-induced T-Cells)

Program: CI Funding Line: UPGRADE Project type: study-related research project Partner site: Berlin, Essen/Dusseldorf, Munich, Tubingen Entity: blood cancer Status: current

iVacALL (Prospective phase I/II study: Patient-individualized peptide vaccination based on whole exome sequencing with adjuvant GM-CSF and IFNa in children with relapsed acute lymphoblastic leukemia)

Program: CI Funding Line: INNOVATION Project type: IIT/clinical study Partner site: Berlin, Essen/Dusseldorf, Heidelberg, Munich, Tubingen Entity: blood cancer Status: completed

JF-PSMA (Combined molecular and imaging-based characterization and prognostication of primary high risk prostate cancer from the multicenter 68Ga-PSMA-11 DKTK trial)

Program: ROI Funding Line: UPGRADE Project type: study-related research project Partner site: Dresden, Essen/Dusseldorf, Freiburg, Heidelberg, Munich Entity: prostate cancer Status: current

JIP (DKTK Joint Imaging Platform)

Programs: Overarching Funding Line: strategic initiative Project type: technology platform Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: multiple entities Status: current

  • 1 (current)
  • 2
  • 3